TY  - JOUR
AU  - Farooq, Minaam
AU  - Scalia, Gianluca
AU  - Umana, Giuseppe E
AU  - Parekh, Urja
AU  - Naeem, Faiza
AU  - Abid, Sayeda Fatima
AU  - Khan, Muhammad Hammad
AU  - Zahra, Shah Gul
AU  - Sarkar, Hrishikesh P
AU  - Chaurasia, Bipin
TI  - A Systematic Review of Nanomedicine in Glioblastoma Treatment: Clinical Efficacy, Safety, and Future Directions.
JO  - Brain Sciences
VL  - 13
IS  - 12
SN  - 2076-3425
CY  - Basel
PB  - MDPI AG
M1  - DKFZ-2023-02810
SP  - 1727
PY  - 2023
AB  - (1) Background: Glioblastoma (GBM) is categorized as a grade IV astrocytoma by the World Health Organization (WHO), representing the most aggressive and prevalent form of glioma. It presents a significant clinical challenge, with limited treatment options and poor prognosis. This systematic review evaluates the efficacy and safety of various nanotherapy approaches for GBM and explores future directions in tumor management. Nanomedicine, which involves nanoparticles in the 1-100 nm range, shows promise in improving drug delivery and targeting tumor cells. (2) Methods: Following PRISMA guidelines, a systematic search of databases including Google Scholar, NCBI PubMed, Cochrane Library, and ClinicalTrials.gov was conducted to identify clinical trials on GBM and nanomedicine. The primary outcome measures were median overall survival, progression-free survival, and quality of life assessed through Karnofsky performance scores. The safety profile was assessed by adverse events. (3) Results: The analysis included 225 GBM patients, divided into primary and recurrent sub-populations. Primary GBM patients had a median overall survival of 6.75 months, while recurrent GBM patients had a median overall survival of 9.7 months. The mean PFS period was 2.3 months and 3.92 months in primary GBM and recurrent GBM patients, respectively. Nanotherapy showed an improvement in quality of life, with KPS scores increasing after treatment in recurrent GBM patients. Adverse events were observed in 14.2
KW  - glioblastoma (Other)
KW  - molecular markers (Other)
KW  - nanomedicine (Other)
KW  - nanoparticles (Other)
KW  - quality of life (Other)
KW  - theranostics (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38137175
C2  - pmc:PMC10742051
DO  - DOI:10.3390/brainsci13121727
UR  - https://inrepo02.dkfz.de/record/286593
ER  -